Stockreport
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ...
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago.The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The company previously announced positive topline results from PANOVA-3 that demonstrated the trial met its primary endpoint, achieving a statistically significant improvement in median overall survival in patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel compared to those treated with gemcitabine and nab-paclitaxel alone.Data Presentation DetailsOral Presentation: Late Breaking Abstract 4005: PANOVA-3: Phase 3 study of tumor
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | NVCR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
NVCR alerts
NVCR alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
NEWS
NEWS
- Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference[Business Wire]
- Novocure names Frank Leonard as CEO [Seeking Alpha][Seeking Alpha]
- Novocure Appoints Company President Frank Leonard as Chief Executive Officer[Business Wire]
- Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference[Business Wire]
- Novocure to Participate in 2025 Jefferies Global Healthcare Conference[Business Wire]
- More
NVCR
SEC Filings
SEC Filings
- 12/1/25 - Form 8-K
- 11/13/25 - Form SCHEDULE
- 11/7/25 - Form SCHEDULE
- NVCR's page on the SEC website
- More